Lendlease new C.E.O. today slashes earnings forecast
SYDNEY: Lendlease’s new chief executive Tony Lombardo has issued a sharp earnings downgrade ... read more
Mesoblast set to line up another FDA chat
MELBOURNE: Shares in stem cell treatments developer Mesoblast opened 3 per cent higher ... read more
Crescent seeks buyer for clinical trials biz Nucleus
MELBOURNE: Australian private equity firm Crescent Capital Partners has put its clinical research ... read more
